Related references
Note: Only part of the references are listed.The effect of hydroxyurea in spinal muscular atrophy cells and patients
Wen-Chen Liang et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Daily salbutamol in young patients with SMA type II
Marika Pane et al.
NEUROMUSCULAR DISORDERS (2008)
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
C. Angelozzi et al.
JOURNAL OF MEDICAL GENETICS (2008)
A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy
Myriam Vezain et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2007)
The Hammersmith functional score correlates with the SMN2 copy number:: A multicentric study
F. D. Tiziano et al.
NEUROMUSCULAR DISORDERS (2007)
Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA
L. R. Simard et al.
NEUROLOGY (2007)
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
E. Mercuri et al.
NEUROLOGY (2007)
Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy
Conrad C. Weihl et al.
NEUROLOGY (2006)
In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate
Lars Brichta et al.
ANNALS OF NEUROLOGY (2006)
Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number
B Wirth et al.
HUMAN GENETICS (2006)
SMN mRNA and protein levels in peripheral blood - Biomarkers for SMA clinical trials
CJ Sumner et al.
NEUROLOGY (2006)
A novel cell immunoassay to measure survival of motor neurons protein in blood cells
SJ Kolb et al.
BMC NEUROLOGY (2006)
Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells
SM Grzeschik et al.
ANNALS OF NEUROLOGY (2005)
Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy
J Jarecki et al.
HUMAN MOLECULAR GENETICS (2005)
Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients
C Brahe et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2005)
TaqMan amplification system with an internal positive control for HCV RNA quantitation
S Castelain et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy
C Andreassi et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2004)
Evidence for a modifying pathway in SMA discordant families:: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1
C Helmken et al.
HUMAN GENETICS (2003)
Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
L Brichta et al.
HUMAN MOLECULAR GENETICS (2003)
Tissue-specific expression pattern of bovine prion gene: quantification using real-time RT-PCR
A Tichopad et al.
MOLECULAR AND CELLULAR PROBES (2003)
Valproic acid increases SMN levels in spinal muscular atrophy patient cells
CJ Sumner et al.
ANNALS OF NEUROLOGY (2003)
The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation
M Main et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2003)
Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy
M Feldkötter et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Treatment of spinal muscular atrophy by sodium butyrate
JG Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
